Providing laboratory support testing for a clinical trial by meeting trial sponsors’ growing needs, all while meeting stringent regulatory requirements? It’s possible.
Flow Cytometry Blog
What is Cytokine Release Syndrome (CRS)?
Cytokine-associated toxicity, also known as cytokine release syndrome (CRS), is a non–antigen-specific toxicity that occurs as a result of high-level immune activation and can be triggered by a variety of factors such as certain drugs and infections. As the name implies, several cytokines are released and elevated during CRS. The main cytokines implicated during the pathogenesis of CRS include interleukin-6 (IL-6), tumor necrosis factor (TNF-α), interferon-γ (IFN-γ) and interleukin-10 (IL-10) (Fig.1).
Posted in Covid19
After more than two long months of social distancing, wearing masks, and working from home, we are all looking forward to life returning to its normal state. But one of the biggest hurdles to overcome for returning to normal social and economic activities in achieving so-called ‘herd immunity for COVID-19’
During the initial outbreak of the SARS-CoV-2 Global pandemic, children, in general, appeared to be relatively resilient against the virus, with only 2% of reported cases in patients under 20 years old; and world-wide, epidemiologists identified older populations with underlying conditions as being at most risk (Ludvigsson, J. F. 2020).
The challenges, the pitfalls and how we make use of it all?
In the long-term fight against the spread of SARS-CoV-2, a second round of testing tools has been pushed to the front of the media coverage- so called ‘Serological Testing’. There has been confusion as to what these tests are, and what long-term value they can provide to this now Global pandemic. So how do we disseminate this information and determine what makes a valid serological test for SARS-CoV-2, and exactly what do we do with this information?